Syed Yousuf Zafar, MD

Associate Professor of Medicine
Associate Professor in the Sanford School of Public Policy
Affiliate, Duke Global Health Institute
Member of the Duke Cancer Institute
Member in the Duke Clinical Research Institute
Campus mail Duke Box 3505, Durham, NC 27710
Phone (919) 684-8111
Email address yousuf.zafar@duke.edu

Dr. Zafar is a health services researcher with a focus in improving care delivery for patients with advanced cancer. He has obtained advanced training in health services research and has participated in single-institution, multi-institution and national studies focusing on access to care, cost of care, and comparative effectiveness of care delivery between health systems. His primary area of interest is in the cost of cancer care. He has conducted institutional and national studies on how treatment-related costs impact cancer patients' experience. His current work in this arena is focused on patient preferences regarding cost-related communication and decision-making.

A second field of interest is palliative care. Dr. Zafar has collaborated with national and international palliative care leaders to improve the design and delivery of palliative care in cancer clinical trials. Methodologically, this work has centered around systematic literature reviews, iterative surveys, and prospective clinical trials.

Dr. Zafar is a member of the American Society of Clinical Oncology’s Health Disparities and Clinical Practice Guideline Committees. He is a member of the Alliance for Clinical Trials in Oncology's Health Disparities and Health Outcomes Committees. Dr. Zafar's work has been funded by the American Cancer Society, the HealthWell Foundation, the Duke Cancer Prevention and Control Program, the Duke Clinical Research Institute, and the CALGB Foundation.

In Their Words

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 2005 - 2008
  • Resident, Medicine, University of Cincinnati, 2002 - 2005
  • M.D., University of Toledo, 2002

Publications

Strickler, JH, Starodub, AN, Jia, J, Meadows, KL, Nixon, AB, Dellinger, A, Morse, MA, Uronis, HE, Marcom, PK, Zafar, SY, Haley, ST, and Hurwitz, HI. "Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors." Cancer Chemother Pharmacol 70, no. 2 (August 2012): 251-258.

PMID
22744359
Full Text

Vlahovic, G, Meadows, KL, Uronis, HE, Morse, MA, Blobe, GC, Riedel, RF, Zafar, SY, Alvarez-Secord, A, Gockerman, J, Starodub, AN, Ready, NE, Anderson, EL, Bendell, JC, and Hurwitz, HI. "A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors." Cancer Chemother Pharmacol 70, no. 1 (July 2012): 95-102.

PMID
22638798
Full Text

Palta, M, Patel, P, Broadwater, G, Willett, C, Pepek, J, Tyler, D, Zafar, SY, Uronis, H, Hurwitz, H, White, R, and Czito, B. "Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy." Ann Surg Oncol 19, no. 5 (May 2012): 1535-1540.

PMID
22045467
Full Text

Currow, DC, Tieman, JJ, Greene, A, Zafar, SY, Wheeler, JL, and Abernethy, AP. "Refining a checklist for reporting patient populations and service characteristics in hospice and palliative care research." J Pain Symptom Manage 43, no. 5 (May 2012): 902-910.

PMID
22445274
Full Text

Rangwala, F, Zafar, SY, and Abernethy, AP. "Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach." Curr Opin Support Palliat Care 6, no. 1 (March 2012): 69-76. (Review)

PMID
22228030
Full Text

Zafar, SY, Currow, DC, Cherny, N, Strasser, F, Fowler, R, and Abernethy, AP. "Consensus-based standards for best supportive care in clinical trials in advanced cancer." Lancet Oncol 13, no. 2 (February 2012): e77-e82. (Review)

PMID
22300862
Full Text

Zafar, SY, Malin, JL, Grambow, SC, Abbott, DH, Schrag, D, Kolimaga, JT, Zullig, LL, Weeks, JC, Fouad, MN, Ayanian, JZ, Wallace, R, Kahn, KL, Ganz, PA, Catalano, P, West, DW, Provenzale, D, and Cancer Care and Outcomes Research and Surveillance (CanCORS) Consortium, . "Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. (Published online)" BMC Cancer 11 (August 16, 2011): 354-.

PMID
21846341
Full Text

Currow, DC, Foley, K, Zafar, SY, Wheeler, JL, and Abernethy, AP. "The need for a re-evaluation of best supportive care studies reported to date." Br J Cancer 104, no. 3 (February 1, 2011): 390-391.

PMID
21285970
Full Text

Bullock, KE, Petros, WP, Younis, I, Uronis, HE, Morse, MA, Blobe, GC, Zafar, SY, Gockerman, JP, Lager, JJ, Truax, R, Meadows, KL, Howard, LA, O'Neill, MM, Broadwater, G, Hurwitz, HI, and Bendell, JC. "A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)." Cancer Chemother Pharmacol 67, no. 2 (February 2011): 465-474.

PMID
21079958
Full Text

Hirsch, BR, and Zafar, SY. "Capecitabine in the management of colorectal cancer." Cancer Manag Res 3 (2011): 79-89.

PMID
21629830
Full Text

Pages